LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Immune Profiles Evolution Under Immunotherapy for Melanoma
- Status
- RECRUITING
- Phase
- NA
Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for General Practitioners
- Status
- COMPLETED
- Phase
- NA
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)
- Status
- COMPLETED
- Phase
- NA
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- Status
- RECRUITING
- Phase
- N/A
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
- Status
- AVAILABLE
- Phase
- N/A
Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Status
- RECRUITING
- Phase
- NA
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- Status
- WITHDRAWN
- Phase
- PHASE2
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
- Status
- RECRUITING
- Phase
- N/A
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
- Status
- COMPLETED
- Phase
- N/A
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A